Compare Stocks → Your $200 account credit is about to expire (From MarketBeat) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BLUSFNASDAQ:CNSTNASDAQ:NXTCNASDAQ:PRNBNASDAQ:TBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ANXTCNextCure$2.23+14.9%$1.48$0.98▼$2.28$62.22M0.37254,669 shs1.02 million shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/ATBPHTheravance Biopharma$8.97-0.4%$9.01$8.21▼$12.03$432.09M0.36369,312 shs401,710 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%+105.87%CNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NXTCNextCure-1.78%+37.23%+29.00%+68.26%+26.47%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%TBPHTheravance Biopharma+2.15%0.00%-2.38%-20.34%-14.84%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure4.5466 of 5 stars3.53.00.04.42.91.71.3PRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATBPHTheravance Biopharma1.9096 of 5 stars3.51.00.00.02.42.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS HealthN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/ANXTCNextCure3.00Buy$6.00169.06% UpsidePRNBPrincipia BiopharmaN/AN/AN/AN/ATBPHTheravance Biopharma3.00Buy$20.00122.97% UpsideCurrent Analyst RatingsLatest NXTC, PRNB, CNST, TBPH, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.001/8/2024TBPHTheravance BiopharmaEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/APRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14TBPHTheravance Biopharma$57.42M7.52N/AN/A$4.28 per share2.10Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/ANXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/ATBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)Latest NXTC, PRNB, CNST, TBPH, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87CNSTConstellation PharmaceuticalsN/A15.3915.39NXTCNextCureN/A16.3816.38PRNBPrincipia BiopharmaN/A17.0117.01TBPHTheravance BiopharmaN/A5.395.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/ACNSTConstellation PharmaceuticalsN/ANXTCNextCure42.65%PRNBPrincipia Biopharma95.54%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%CNSTConstellation Pharmaceuticals43.70%NXTCNextCure11.90%PRNBPrincipia Biopharma16.01%TBPHTheravance Biopharma5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableNXTCNextCure8227.90 million24.58 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableTBPHTheravance Biopharma35948.17 million45.61 millionOptionableNXTC, PRNB, CNST, TBPH, and BLUSF HeadlinesSourceHeadlineWhy Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?zacks.com - March 27 at 12:36 PMTheravance Biopharma (NASDAQ:TBPH) Shares Cross Below 50-Day Moving Average of $9.04americanbankingnews.com - March 26 at 5:14 AMTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04marketbeat.com - March 26 at 5:14 AMZacks Research Weighs in on Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)americanbankingnews.com - March 18 at 1:28 AMEquities Analysts Offer Predictions for Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)marketbeat.com - March 18 at 1:27 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn FY2026 Earnings of $0.75 Per Sharemarketbeat.com - March 15 at 7:48 AMJacobs Levy Equity Management Inc. Has $3.52 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - March 15 at 4:15 AMShort-Squeeze Showdown: 3 Stocks Ready to Crush the Skepticsinvestorplace.com - March 12 at 3:59 PMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn Q1 2024 Earnings of ($0.40) Per Sharemarketbeat.com - March 8 at 6:18 AMAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potentialmarkets.businessinsider.com - March 7 at 9:55 AMFY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs (NASDAQ:TBPH)marketbeat.com - March 7 at 7:53 AMTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestonesmarkets.businessinsider.com - February 28 at 10:50 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:50 AMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatestockhouse.com - February 27 at 11:30 PMTheravance Biopharma Inc (TBPH)investing.com - February 27 at 1:29 PMTheravance's (TBPH) Q4 Earnings & Revenues Surpass Estimateszacks.com - February 27 at 12:51 PMBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharmamarkets.businessinsider.com - February 27 at 1:45 AMTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03Mmsn.com - February 26 at 8:44 PMTheravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimateszacks.com - February 26 at 6:26 PMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - February 26 at 4:05 PMTheravance Biopharma Q4 2023 Earnings Previewseekingalpha.com - February 25 at 6:21 PMTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and Datesbenzinga.com - February 24 at 9:19 AMTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03msn.com - February 24 at 9:19 AMTheravance Biopharma to Participate in an Upcoming Investor Conferenceprnewswire.com - February 22 at 6:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Constellation PharmaceuticalsNASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Principia BiopharmaNASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.